Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Radiofrequency ablation following first-line transarterial chemoembolization for patients with unresectable hepatocellular carcinoma beyond the Milan criteria

  • Lan Zhang1, 2,
  • Xin Yin1, 2,
  • Yu-hong Gan1, 2,
  • Bo-heng Zhang1, 2,
  • Ju-bo Zhang1, 2,
  • Yi Chen1, 2,
  • Xiao-ying Xie1, 2,
  • Ning-lin Ge1, 2,
  • Yan-hong Wang1, 2,
  • Sheng-long Ye1, 2 and
  • Zheng-gang Ren1, 2Email author
BMC GastroenterologyBMC series ¿ open, inclusive and trusted201414:11

DOI: 10.1186/1471-230X-14-11

Received: 9 May 2013

Accepted: 3 January 2014

Published: 10 January 2014

Abstract

Background

Recent studies suggest that a combination of radiofrequency ablation (RFA) and transarterial chemoembolization (TACE) may have theoretical advantages over TACE alone for treatment of hepatocellular carcinoma (HCC). The purpose of this study was to evaluate the effectiveness and safety of radiofrequency ablation following first-line TACE treatment in the management of HCC beyond the Milan Criteria.

Methods

Forty-five patients who consecutively underwent RFA following first-line TACE treatment for HCC beyond the Milan criteria were enrolled in this study. RFA was performed within 1–2 months after TACE treatment in patients who had incomplete necrotic tumor nodules. Primary effectiveness, complications, survival rates, and prognostic factors were evaluated retrospectively.

Results

Complete ablation was achieved in 76.2% of the lesions according to 1-month follow-up computed tomography/magnetic resonance imaging evaluation. The mean follow-up period was 30.9 months (range 3–94 months). There were no major complications after RFA therapy. The median overall survival was 29 months (range 20–38 months), with 1-, 2-, and 3-year survival of 89%, 61%, and 43%, respectively. Multivariate analysis revealed that tumor diameter (P = 0.045, hazard ratio [HR] = 0.228, 95% confidence interval [CI]: 0.054-0.968) and pretreatment serum alpha-fetoprotein level (P = 0.024, HR = 2.239, 95% CI: 1.114-4.500) were independent predictors for long-term survival.

Conclusions

HCC beyond the Milan criteria can be completely and safely ablated by radiofrequency ablation following first-line TACE treatment with a low rate of complications and favorable survival outcome. Further assessment of the survival benefits of combination treatment for HCCs beyond the Milan Criteria is warranted.

Keywords

Hepatocellular carcinoma Radiofrequency ablation Transcatheter arterial chemoembolization Milan criteria

Background

Hepatocellular carcinoma (HCC) is the third most common cause of cancer-related mortality worldwide and the second most common in China [1, 2]. Despite increased early diagnosis of HCC as a result of surveillance of high-risk populations, only 30% of patients diagnosed with early stage HCC are candidates for curative therapies such as surgical resection or radiofrequency ablation [3]. Moreover, the prognosis of patients with advanced or unresectable HCC remains unsatisfactory due to a low response rate and short time to progression. According to current treatment guidelines, transcatheter arterial chemoembolization (TACE) has been established as the standard therapy for patients who are not eligible for curative therapies [4, 5]. Although the survival benefit of TACE treatment has been proved in two randomized clinical trials [5, 6], TACE has a primarily palliative effect and does not achieve complete tumor necrosis therefore tumor relapse after TACE is universal [7]. Additionally, repetitive TACE treatments might damage liver function reserve and decrease survival time. Consequently, new strategies are needed to improve the effectiveness of TACE treatment for HCC patients.

Percutaneous radiofrequency ablation (RFA) has been accepted as a curative therapy for small HCC, and can provide better local control of the disease than TACE treatment and a similar long-term survival to surgical resection. Previous studies have shown that RFA can achieve complete necrosis in more than 90% of small HCCs [810]. Nevertheless, the effectiveness of RFA treatment in patients with intermediate or large HCC is unsatisfactory, with a relatively low complete necrosis rate ranging from 29.0% to 70.0% even if overlapping ablation or repeated procedures are used [1113]. Therefore, conventional RFA treatment was recommended only for patients with small HCCs confined to the Milan criteria [14].

Recent evidence has suggested that TACE combined with RFA may have a synergistic effect on ablation of HCC [1517]. To date, few studies have investigated combination therapy of radiofrequency ablation following transarterial arterial chemoembolization for patients with unresectable HCC beyond the Milan criteria. The aim of this study was to evaluate the effectiveness and safety of such combination therapy for unresectable HCC.

Methods

Patient enrollment

This survey is a retrospective study in a single center. The TACE or RFA treatment procedures were according to our institutional standard treatment protocol at Zhongshan hospital, Fudan University. The Medical Ethics Committee of Shanghai Zhongshan Hospital provided ethics approval for this retrospective study. From February 2001 to November 2009, a total of 611 consecutive HCC patients with unresectable tumors were treated with RFA in the Liver Cancer Institute, Zhongshan Hospital. All patients had a prospectively established database covering patient demographics, the etiology of the underlying liver disease, tumor-related characteristics, serum biochemistries, and survival data. Patient selection was performed using the following inclusion criteria: (1) diagnosis of HCC confirmed pathologically or in accordance with American Association for the Study of Liver Diseases criteria [18]; (2) HCC beyond the Milan Criteria (single nodule with size ≤5 cm or three nodules or fewer with tumor size ≤3 cm) that was treated with TACE as the first-line therapy; (3) tumor nodules to be ablated should be clearly observed by ultrasound and there should be no contraindications of RFA therapy; (4) no portal vein involvement or distant metastasis; (5) liver function of Child-Pugh A-B; (6) complete clinicopathologic and follow-up data. Ultimately, 45 patients were included in this study. Patient characteristics are shown in Table 1.
Table 1

Baseline characteristics of patients treated with RFA after first-line treatment with TACE

Characteristics

No. of patients (%)

Age (years)

 

 <60

27 (60.0)

 ≥60

18 (40.0)

Child-Pugh classification

 

 A

45 (100.0)

 B

0 (0.0)

 C

0 (0.0)

Gender

 

 Male

39 (86.7)

 Female

6 (13.3)

HBsAg

 

 Positive

36 (80.0)

 Negative

9 (20.0)

Anti-HCV

 

 Positive

2 (4.4)

 Negative

43 (95.6)

AFP

 

 <400 ng/ml

25 (55.6)

 ≥400 ng/ml

20 (44.4)

Ablation nodules

84

 Single

20 (23.8)

 Multiple

64 (76.2)

Tumor diameter with ablation

 

 ≤5 cm

44 (52.4)

 >5 cm

40 (47.6)

TACE procedure

TACE was performed using a standard procedure. Briefly, hepatic arteriography was performed to identify the feeding artery of the liver tumor. The catheter, usually a 4 F or 5 F RH catheter (Cook Co., USA), was inserted into the tumor feeding artery as close as possible to the tumor. Microcatheters (Terumo Co., Japan) were used to catheterize the feeding artery if needed. Chemotherapeutic agents [1000 mg 5-fluoruracil (5-FU), 80 mg cisplatin] were slowly infused followed by 5–30 ml lipiodol with 10 mg mitomycin-C emulsion for embolization. The regimen of chemoembolization was adjusted according to liver function and peripheral leukocyte or platelet levels. Gelatin was administered afterwards for additional embolization in cases with large hypervascular tumors.

RFA procedure

Before RFA treatment, a dynamic contrast computed tomograph (CT) or magnetic resonance imaging (MRI) was performed to evaluate the response after TACE and identify the target lesions to be treated with RFA. Disappearance of tumor enhancement in the arterial phase was considered complete necrosis and identified tumor nodules that were not targets for RFA. Only tumor nodules with contrast enhancement in arterial phase with CT or MRI evaluation were treated with RFA.

From February 2001 to September 2004, 16 patients were treated with RFA using the RFA 2000 (Radio-Therapeutic, USA) and a needle electrode with a 15-gauge insulated cannula and 10 hook-shaped expandable electrode tines with a diameter of 2.0 or 3.5 cm at expansion (Radio-Therapeutics,USA). From October 2004 to November 2009, 29 patients were treated with RFA using a 15-gauge multielectrode RF probe with an expansion of 2.0 or 3.5 cm (RITA, USA). The details of the treatment procedure are described in our previous studies [19]. Briefly, RFA was performed by a percutaneous procedure under conscious sedation and local anesthesia. The RFA electrode was inserted into the tumor nodules under the guidance of ultrasonography. Overlap ablation was allowed to cover the whole tumor nodule and achieve an adequate safety margin of 0.5-1.0 cm.

Evaluation of ablation efficiency and follow-up

The ablation efficiency of RFA was evaluated after 1 month by dynamic contrast-enhanced CT or MRI. Complete ablation (complete response [CR]) was defined as complete devascularization of the lesions during the arterial phase and no appearance of new tumors at other liver sites. Patients were monitored every 2 months after RFA by serum alpha-fetoprotein (AFP) levels and abdominal ultrasonography. Patients with test results suggestive of recurrence or metastasis received additional computed tomography and/or magnetic resonance imaging. Patients with local incomplete ablation or residual disease in the remaining liver underwent a repeat RFA or chemoembolization.

Statistical analysis

Quantitative variables were expressed as means ± standard deviation or as medians. Qualitative variables were presented as numbers and percentages. Student’s t test was used to compare quantitative variables and the χ2 test was used for qualitative variables. Overall survival (OS) was calculated from the date of TACE treatment to death or the last follow-up. Survival curves were constructed by the Kaplan-Meier method. Multivariate analysis was performed using the Cox proportional hazards models. A difference was considered significant for P <0.05.

Results

Efficiency of ablation

We evaluated a total of 147 tumor nodules in 45 patients (10 patients with single nodule; 11 with 2 nodules, 2 with 3 nodules, and 22 with 4–5 nodules). Among the 147 nodules, 84 were treated with the RFA procedure. The other 63 nodules were not treated with RFA because of complete necrosis presenting with complete lipiodol deposition and without artery contrast enhancement on CT or MRI after TACE treatment. For the ablated tumor lesions, 44 lesions were ≥50 mm and 40 lesions were <50 mm, with a median tumor diameter of 55.0 mm (range 20 mm to 80 mm) (Table 1).

Complete ablation was achieved in 64 of 84 (76.2%) lesions (Figure 1). The remaining 20 (23.8%) lesions were identified as residual disease attributed to incomplete ablation on CT/MRI images (Figure 2). The ablation efficiency showed a significant correlation with the size of the lesion: lesions <50 mm had a higher complete ablation rate than lesions ≥50 mm with complete ablation rates of 86.4% (38/44) and 65% (26/40), respectively (P = 0.022). However, the number of lesions had no impact on the complete ablation rate. Complete ablation was achieved in 51 of 64 (79.7%) lesions in the 25 patients with multifocal tumors, compared with 13 of 20 (65.0%) lesions in the 20 patients with a single lesion. There was no significant difference between patients with single or multiple nodules (P = 0.178) (Table 2).
https://static-content.springer.com/image/art%3A10.1186%2F1471-230X-14-11/MediaObjects/12876_2013_Article_1043_Fig1_HTML.jpg
Figure 1

Complete ablation of HCC. A: MRI image before TACE; B: CT image before RFA; C: MRI image after RFA.

https://static-content.springer.com/image/art%3A10.1186%2F1471-230X-14-11/MediaObjects/12876_2013_Article_1043_Fig2_HTML.jpg
Figure 2

Incomplete ablation of HCC. A: CT image before RFA; B and C: MRI image after RFA.

Table 2

Evaluation of factors affecting ablation efficiency

Prognostic factor

Local success (CR)

P value

Tumor diameter

  

 ≤5 cm

86.4% (38/44)

0.022

 >5 cm

65.0% (26/40)

 

Tumor number

  

 Single

65.0% (13/20)

0.178

 Multiple

79.7% (51/64)

 

Survival

During a median follow-up of 30.9 months (range 3–94 months), 33 patients died from intrahepatic recurrence and three patients died from non-HCC related causes. The median OS was 29 months (range: 20–38 months) with 1-, 2- and 3-year overall survival rates of 89%, 61%, and 43%, respectively (Figure 3A).
https://static-content.springer.com/image/art%3A10.1186%2F1471-230X-14-11/MediaObjects/12876_2013_Article_1043_Fig3_HTML.jpg
Figure 3

Survival curves of patients treated with RFA after first-line treatment with TACE. A: Overall cumulative survival of 45 patients treated with RFA after first-line treatment with TACE; B: Cumulative survival according to AFP level; C: Cumulative survival according to tumor size.

Complications

Two of 45 patients (4.4%) developed procedure-related major complications after RFA (one with local skin heat injury and one with gastrointestinal bleeding). No procedure-related deaths occurred. Minor complications such as nausea, fever, and post-treatment abdominal pain were observed in most patients but none required medical intervention.

Prognostic factors

The prognostic factors used for univariate analysis included the variables of demographics, liver function, and tumor-related characteristics. Significant prognostic factors are shown in Table 3 and Figure 3.
Table 3

Univariate analysis of prognostic factors in patients treated with RFA after first-line treatment with TACE

Variable

No. of patients (%)

OS (months)

P value

Age (years)

   

 ≥60

18 (40)

34

0.708

 <60

27 (60)

27

 

Gender

   

 Male

39 (86.7)

34

0.388

 Female

6 (13.3)

20

 

AFP

   

 ≥400 ng/ml

20 (44.4)

20

0.015

 <400 ng/ml

25 (55.6)

43

 

Lesion size

   

 ≥50 mm

41 (91.1)

41

0.028

 <50 mm

4 (8.9)

22

 

Lesion number

   

 Single

10 (22.2)

29

0.888

 Multiple

35 (77.8)

28

 

ALT

   

 ≥75 U/L

9 (20.0)

38

0.828

 <75 U/L

36 (80.0)

42

 

GGT

   

 ≥100 U/L

21 (46.7)

34

0.869

 <100 U/L

24 (53.3)

27

 

ALB

   

 ≥35 g/L

38 (84.4)

34

0.078

 <35 g/L

7 (15.6)

20

 

PT

   

 ≥13 s

7 (15.6)

20

0.059

 <13 s

38 (84.4)

34

 
Multivariate analysis confirmed that tumor diameter (P = 0.045, hazard ratio [HR]: 0.228, 95% confidence interval [CI]: 0.054-0.968) and pretreatment serum AFP level (P = 0.024, HR: 2.239, 95% CI: 1.114-4.500) were independent predictors for survival (Table 4).
Table 4

Multivariate analysis of prognostic factors in patients with RFA after first-line treatment with TACE

Variable

P value

RR

95% CI

AFP

0.024

2.239

1.114-4.500

Tumor size

0.045

0.228

0.054-0.968

Tumor number

0.565

0.775

0.325-1.848

Discussion

RFA has been widely used as a curative therapy for small HCC. The overall survival of patients with small HCC undergoing RFA is similar to that of patients receiving surgical Resection [810, 20, 21]. In clinical practice it is rarely possible to achieve complete ablation for tumors larger than 5 cm because of the limitation of the ablation zone [22, 23]. For patients with tumors beyond the Milan criteria, surgical treatment could be another curative option. If the tumor cannot be completely removed, palliative TACE treatment is the main treatment of choice. However, the long-term outcome for patients with unresectable HCC treated with TACE is unsatisfactory due to the inability to achieve complete tumor necrosis. Repeated TACE is often needed to completely eradicate the residual tumors, but its efficiency is limited and the rate of tumor recurrence or relapse after initial remission or stable disease is very high.

Several lines of evidence have indicated the feasibility and benefit of combination therapy of TACE and RFA. Buscarini et al. treated 14 HCC patients (with lesion size ranging from 3.8-6.8 cm, median 5.2 cm) with TACE followed by RFA. Their results suggested the possibility of treating large HCC with this procedure [24]. Lencioni et al. similarly reported a successful outcome (82%) among patients with HCC (lesion size ranging between 3.8 and 8.5 cm) who were treated with TACE prior to RFA [25]. Consistent with previous studies, the post-treatment CR rate of 76.2% and partial response rate of 23.8% in the present series indicate an encouraging benefit for patients with unresectable HCC beyond the Milan criteria.

RFA treatment following TACE has some advantages over TACE alone. Embolization during the TACE procedure can block arterial flow, which may reduce heat-sink effects during RFA thus increasing the volume of the zone of ablation and reducing the chance of tumor recurrence. TACE can also control or eliminate micro-metastasis, which cannot always be detected by ultrasonography, CT, or MRI. Thus, the addition of TACE may decrease the chance of micro-metastasis after RFA treatment in HCC patients with unresectable tumors beyond the Milan criteria.

With respect to prognostic factors correlated with local ablation efficiency, our results suggested that lesion diameter (< 50 mm vs. ≥ 50 mm) was statistically significant for predicting complete ablation (86.4% vs. 65%, P = 0.022). The presence of multiple lesions did not significantly affect complete ablation, although this might be because the number of nodules was confined to five in our study. It is difficult to completely destroy tumors larger than 5 cm by RFA despite multiple overlapping ablations; however, first-line TACE treatment might reduce the volume of viable tumor thus making complete ablation of the lesions possible. This treatment advantage was also proposed by Vogl, who suggested that repeated TACE might reduce the size of the treated lesions [26].

In this study, the 1-, 2-, and 3-year survival rates were 89%, 61%, and 43%, respectively. These rates are consistent with those of other studies. Veltri reported 1- and 2-year survival rates of 89.7% and 67.1% for TACE-RFA combined therapy for unresectable non-early HCC (size 30–80 mm, mean 48.9 mm) [27]. Similarly, Liao et al. [28] administrated TACE followed by RFA in the treatment of unresectable HCC (size 30–120 mm, mean 58.9 mm) with 1-, 2- and 3-year survival rates of 84%, 57%, and 38%, respectively. Our multivariate analysis showed that tumor size and serum AFP level before treatment were prognostic factors for overall survival. A high pretreatment level of AFP has previously been reported to be associated with poorer survival, reflecting not only tumor cell proliferation but also active disease with continuous necrosis and regeneration [29, 30].

We found that TACE-RFA combined therapy had a low rate of major complications. No permanent adverse sequelae or treatment-related deaths were observed. Thus, combination therapy of TACE followed by RFA appears to be relatively safe.

Conclusion

In conclusion, our results indicate that combination therapy of TACE with RFA is safe and effective, and can achieve a favorable long-term outcome in unresectable HCC beyond the Milan criteria. The major limitation of this study was its retrospective nature and non-randomized design. Further prospective randomized studies are warranted to confirm the efficacy of this promising combination therapy.

Abbreviations

5-FU: 

5-fluorouracil

AFP: 

Alpha-fetoprotein

CR: 

Complete response

CT: 

Computed tomography

HCC: 

Hepatocellular carcinoma

MRI: 

Magnetic resonance imaging

OS: 

Overall survival

RFA: 

Radiofrequency ablation

TACE: 

Transcatheter arterial chemoembolization.

Declarations

Acknowledgments

This study was supported by a grant from the Zhongshan Hospital Clinical Research Development Program. We thank Xiaomei yang at Cancer Liver Institute for the data collection and Weizhong Chen at radiology department for providing imaging information.

Authors’ Affiliations

(1)
Liver Cancer Institute, Zhongshan Hospital, Fudan University
(2)
Key Laboratory of Carcinogenesis and Cancer Invasion (Fudan University), Ministry of Education

References

  1. Ding SJ, Li Y, Tan YX, Jiang MR, Tian B, Liu YK, Shao XX, Ye SL, Wu JR, Zeng R, Wang HY, Tang ZY, Xia QC: From proteomic analysis to clinical significance: overexpression of cytokeratin 19 correlates with hepatocellular carcinoma metastasis. Mol Cell Proteomics. 2004, 3: 73-81.View ArticlePubMed
  2. Altekruse SF, McGlynn KA, Reichman ME: Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol. 2009, 27: 1485-1491. 10.1200/JCO.2008.20.7753.PubMed CentralView ArticlePubMed
  3. Sangiovanni A, Del Ninno E, Fasani P, De F, Ronchi G, Romeo R, Morabito A, De Franchis R, Colombo M: Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology. 2004, 126: 1005-1014. 10.1053/j.gastro.2003.12.049.View ArticlePubMed
  4. Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, Ayuso C, Sala M, Muchart J, Sola R, Rodes J, Bruix J: Arterial embolisation or chemoembolisation versus symptomatic treatment in patient with unresectable hepatocellular carcinoma: a randomized controlled trial. Lancet. 2002, 359: 1734-1739. 10.1016/S0140-6736(02)08649-X.View ArticlePubMed
  5. Lo CM, Nqan H, Tso WK, Liu CL, Lam CM, Poon RT, Fan ST, Wong J: Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002, 35: 1164-1167. 10.1053/jhep.2002.33156.View ArticlePubMed
  6. Llovet JM, Bruix J: Systematic review of randomize trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology. 2003, 37: 429-442. 10.1053/jhep.2003.50047.View ArticlePubMed
  7. Jansen MC, van Hillegersberg R, Chamuleau RA, van Delden OM, Gouma DJ, van Guilk TM: Outcome of regional and local ablative therapies for hepatocellular carcinoma: a collective review. Eur J Surg Oncol. 2005, 31: 331-347. 10.1016/j.ejso.2004.10.011.View ArticlePubMed
  8. McGahan JF, Dodd GD: Radiofrequency ablation of the liver: current status. Am J Roentgenol. 2001, 176: 3-16. 10.2214/ajr.176.1.1760003.View Article
  9. Lencioni R, Allgaier HP, Cioni D, Olschewski M, Deibert P, Crocetti L, Fring H, Laubenberger J, Zuber I, Blum HE, Bartolozzi C: Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. Radiology. 2003, 228: 235-240. 10.1148/radiol.2281020718.View ArticlePubMed
  10. Buscarini L, Buscarini E, Di Stasi M, Vallisa D, Quaretti P, Rocca A: Percutaneous radiofrequency ablation of small hepatocellular carcinoma: long term results. Eur Radiol. 2001, 11: 914-921. 10.1007/s003300000659.View ArticlePubMed
  11. Livraghi T, Goldberg SN, Lazzaroni S, Meloni F, Ierace T, Solbiati L, Gazelle GS: Hepatocellular carcinoma: radio-frequency ablation of medium and large lesions. Radiology. 2000, 214: 761-768. 10.1148/radiology.214.3.r00mr02761.View ArticlePubMed
  12. Dupuy DE, Goldberg SN: Image-guided radiofrequency tumor ablation: challenges and opportunities–part II. J Vasc Interv Radiol. 2001, 12: 1135-1148. 10.1016/S1051-0443(07)61670-4.View ArticlePubMed
  13. Curley SA: Radiofrequency ablation of malignant liver tumors. Ann Surg Oncol. 2003, 10: 338-347. 10.1245/ASO.2003.07.017.View ArticlePubMed
  14. Hsu CY, Huang YH, Chiou YY, Su CW, Lin HC, Lee RC, Chiang JH, Huo TI, Lee FY, Lee SD: Comparison of radiofrequency ablation and transarterial chemoembolization for hepatocellular carcinoma within the Milan Criteria: A propensity score analysis. Liver Transpl. 2011, 17: 556-566. 10.1002/lt.22273.View ArticlePubMed
  15. Peng ZW, Chen MS, Liang HH, Gao HJ, Zhang YJ, Li JQ, Zhang YQ, Lau WY: A case–control study comparing percutaneous radiofrequency ablation alone or combined with transcatheter arterial chemoembolization for hepatocellular carcinoma. Eur J Surg Oncol. 2010, 36: 257-263. 10.1016/j.ejso.2009.07.007.View ArticlePubMed
  16. Takaki H, Yamakado K, Uraki J, Nakatsuka A, Fuke H, Yamamoto N, Shiraki K, Yamada T, Takeda K: Radiofrequency ablation combined with chemoembolization for the treatment of hepatocellular carcinomas larger than 5 cm. J Vasc Interv Radiol. 2009, 20: 217-224. 10.1016/j.jvir.2008.10.019.View ArticlePubMed
  17. Kirikoshi H, Saito S, Yoneda M, Fujita K, Mawatari H, Uchiyama T, Higurashi T, Goto A, Takahashi H, Abe Y, Inamori M, Kobayashi N, Kubota K, Sakaguchi T, Ueno N, Nakajima A: Outcome of transarterial chemoembolization monotherapy, and in combination with percutaneous ethanol injection, or radiofrequency ablation therapy for hepatocellular carcinoma. Hepatol Res. 2009, 39: 553-562. 10.1111/j.1872-034X.2009.00490.x.View ArticlePubMed
  18. Bruix J, Sherman M: Management of hepatocellular carcinoma: an update. Hepatology. 2011, 53: 1020-1022. 10.1002/hep.24199.PubMed CentralView ArticlePubMed
  19. Yang B, Zou J, Xia J, Ren Z, Gan Y, Wang Y, Zhang B, Ge N, Wang D, Chen Y, Chen R, Li L, Ye S, Wang X: Risk factors for recurrence of small hepatocellular carcinoma after long-term follow-up of precutaneous radiofrequency ablation. Eur J Radiol. 2011, 79: 196-200. 10.1016/j.ejrad.2010.02.010.View ArticlePubMed
  20. Lau WY, Leung TW, Yu SC, Ho SK: Percutaneous local ablative therapy for hepatocellular carcinoma: a review and look into the future. Ann Surg. 2003, 237: 171-179.PubMed CentralPubMed
  21. de Baere T, Elias D, Dromain C, Din MG, Kuoch V, Ducreux M, Boige V, Lassau N, Marteau V, Lasser P, Roche A: Radiofrequency ablation of 100 hepatic metastases with a mean follow-up of more than 1 year. AJR Am J Roentgenol. 2000, 175: 1619-1625. 10.2214/ajr.175.6.1751619.View ArticlePubMed
  22. Yamasaki T, Kurokawa F, Shirahashi H, Kusano N, Hironaka K, Okita K: Percutaneous radiofrequency ablation therapy for patients with hepatocellular carcinoma during occlusion of hepatic blood flow. Comparison with standard percutaneous radiofrequency ablation therapy. Cancer. 2002, 95: 2353-2360. 10.1002/cncr.10966.View ArticlePubMed
  23. Rossi S, Garbagnati F, De Francesco I, Accocella F, Leonardi L, Quaretti P, Zangrandi A, Paties C, Lencioni R: Relationship between the shape and size of radiofrequency-induced thermal lesions and hepatic vascularization. Tumori. 1999, 85: 128-132.PubMed
  24. Buscarini L, Buscarini E, Di Stasi M, Quaretti P, Zangrandi A: Percutaneous radiofrequency thermal ablation combined with transcatheter arterial embolization in the treatment of large hepatocellular carcinoma. Ultraschall Med. 1999, 20: 47-53. 10.1055/s-1999-14233.View ArticlePubMed
  25. Lencioni R, Cioni D, Donati F, Bartolozzi C: Combination of interventional therapies in hepatocellular carcinoma. Hepatogastroenterology. 2001, 48: 8-14.PubMed
  26. Vogl TJ, Mack MG, Balzer JO, Engelmann K, Straub R, Eichler K, Woitaschek D, Zangos S: Liver metastases: neoadjuvant downsizing with trans-arterial chemoembolization before laser-induced thermotheraphy. Radiology. 2003, 229: 457-464. 10.1148/radiol.2292021329.View ArticlePubMed
  27. Veltri A, Moretto P, Doriguzzi A, Pagano E, Carrara G, Gandini G: Radiofrequency thermal ablation (RFA) after transarterial chemoembolization (TACE) as a combined therapy for unresectable non-early hepatocellular carcinoma (HCC). Eur Radiol. 2006, 16: 661-669. 10.1007/s00330-005-0029-9.View ArticlePubMed
  28. Liao GS, Yu CY, Shih ML, Chan DC, Liu YC, Yu JC, Chen TW, Hsieh CB: Radiofrequency ablation after transarterial embolization as therapy for patients with unresectable hepatocellular carcinoma. Eur J Surg Oncol. 2008, 34: 61-66. 10.1016/j.ejso.2007.02.006.View ArticlePubMed
  29. Stuart KE, Anand AJ, Jennins RL: Hepatocellular carcinoma in the United States. Cancer. 1996, 77: 2217-2222. 10.1002/(SICI)1097-0142(19960601)77:11<2217::AID-CNCR6>3.0.CO;2-M.View ArticlePubMed
  30. Mondazzi L, Bottelli R, Brambilla G, Rampoldi A, Rezakovic I, Zavaglia C, Alberti A, Ideo G: Transarterial oily chemoembolization for the treatment of hepatocellular carcinoma:A multivariate analysis of prognostic factors. Hepatology. 1994, 19: 1115-1123. 10.1002/hep.1840190508.View ArticlePubMed
  31. Pre-publication history

    1. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-230X/14/11/prepub

Copyright

© zhang et al.; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.